Role of positron emission tomography with 2-deoxy-2-[ 18 F]fluoro-d-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer

Yoshioka, Masato; Sato, Tsutomu; Furuya, Tomoki; Shibata, Satoshi; Andoh, Hideaki; Asanuma, Yoshihiro; Hatazawa, Jun; Shimosegawa, Eku; Koyama, Kenji; Yamamoto, Yūzō

doi:10.1007/s00535-003-1244-2

Cited by 69 publications

(29 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, although in staging FDG-PET did not perform precisely enough except for detecting bone metastases, by evaluating the SUV, FDG-PET may provide such additional information on the biological aggressiveness of the tumor, and thus play an important role in helping to select patients for subsequent surgical therapy. Some small studies reported that the tumor SUVs were useful in predicting the effectiveness of chemotherapy for unresectable pancreatic cancer [17,26,27] . However, conclusions must await further studies including larger population of patients.…”

Section: The Role Of Fdg-pet In Staging Of the Diseasementioning

confidence: 99%

Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer

Wakabayashi¹,

Nishiyama²,

Otani³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM:To evaluate the role of positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) in the surgical management of patients with pancreatic cancer, including the diagnosis, staging, and selection of patients for the subsequent surgical treatment. METHODS:This study involved 53 patients with proven primary pancreatic cancer. The sensitivity of diagnosing the primary cancer was examined for FDG-PET, CT, cytological examination of the bile or pancreatic juice, and the serum levels of carcinoembrionic antigens (CEA) and carbohydrate antigen 19-9 (CA19-9). Next, the accuracy of staging was compared between FDG-PET and CT. Finally, FDG-PET was analyzed semiquantitatively using the standard uptake value (SUV). The impact of the SUV on patient management was evaluated by examining the correlations between the SUV and the histological findings of cancer. RESULTS:The sensitivity of FDG-PET, CT, cytological examination of the bile or pancreatic juice, and the serum levels of CEA and CA19-9 were 92.5%, 88.7%, 46.4%, 37.7% and 69.8%, respectively. In staging, FDG-PET was superior to CT only in diagnosing distant disease (bone metastasis). For local staging, the sensitivity of CT was better than that of FDG-PET. The SUV did not correlate with the pTNM stage, grades, invasions to the vessels and nerve, or with the size of the tumor. However, there was a statistically significant difference (4.6 ± 2.9 vs 7.8 ± 4.5, P = 0.024) in the SUV between patients with respectable and unresectable disease.CONCLUSION: FDG-PET is thus considered to be useful in the diagnosis of pancreatic cancer. However, regarding the staging of the disease, FDG-PET is not considered to be a sufficiently accurate diagnostic modality. Although the SUV does not correlate with the patho-histological prognostic factors, it may be useful in selecting patients who should undergo subsequent surgical treatment.

show abstract

Section: The Role Of Fdg-pet In Staging Of the Diseasementioning

confidence: 99%

Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer

Wakabayashi¹,

Nishiyama²,

Otani³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…These studies also suggest that 18 FDG-PET can determine the efficacy of treatment for pancreatic cancer and may be beneficial for reducing the number of unnecessary operations. [6][7][8][9][10][11][12][13][14][15] However, the clinical role of 18 FDG-PET in pancreatic cancer is still debated, as there are other studies that do not recognize additive role of 18 FDG-PET in the diagnosis of pancreatic cancer. [16][17][18][19][20] The aim of the current study was to investigate the diagnostic accuracy of 18 FGD-PET and to assess the use of 18 FDG-PET in determining tumor response to concurrent chemoradiation therapy for pancreatic cancer.…”

mentioning

confidence: 99%

The Clinical Usefulness of 18-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis, Staging, and Response Evaluation After Concurrent Chemoradiotherapy for Pancreatic Cancer

Bang

Chung

Park

et al. 2006

Journal of Clinical Gastroenterology

158

View full text Add to dashboard Cite

show abstract

“…Identifying these lesions is key toward the most appropriate treatment. However, smaller lesions, below the size threshold of 1 cm, are reportedly most commonly underdiagnosed (39). Small lung metastasis can also be overlooked on PET but detected on the CT component of the examination, supporting the complementary nature of the 2 modalities (27).…”

Section: Limitations Of Pet/ctmentioning

confidence: 94%

“…PET is more sensitive than CECT for monitoring response to chemoradiation and depicting tumor recurrence after surgery (34,35,37,39). Most (72%-92%) pancreatic adenocarcinomas recur locally within 2 y of surgery (34).…”

Section: Pet/ct Applications Toward Prognosis Response To Therapy Rmentioning

confidence: 99%

PET/CT for Pancreatic Malignancy: Potential and Pitfalls

Jha

Bijan

2015

Journal of Nuclear Medicine Technology

View full text Add to dashboard Cite

Pancreatic malignancy carries a poor prognosis and is the fourth leading cause of cancer-related deaths in the United States. Although conventional imaging with CT and MR remains the main imaging modality, recent times have seen an increase in the applications of PET/CT in the evaluation of pancreatic malignancy. Newer data are becoming available, highlighting the advantages, limitations, and pitfalls in PET/CT imaging of the pancreas. This article highlights the applications of PET/CT in various stages of management of pancreatic malignancy and compares these with conventional imaging with CT and MR.

show abstract

Role of positron emission tomography with 2-deoxy-2-[ 18 F]fluoro-d-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer

Abstract: FDG-PET aids in analysis of the effectiveness of chemotherapy and/or radiotherapy.

Cited by 69 publications

References 12 publications

Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer

Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer

The Clinical Usefulness of 18-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis, Staging, and Response Evaluation After Concurrent Chemoradiotherapy for Pancreatic Cancer

PET/CT for Pancreatic Malignancy: Potential and Pitfalls

Contact Info

Product

Resources

About